MeiraGTx Holdings plc
corporate_fare Company Profile
MeiraGTx Holdings plc (NASDAQ:MGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for MGTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for MGTX spans 10-Q, 8-K, DEF 14A, SCHEDULE 13D/A.
Recent high-impact activity:
- MeiraGTx Narrows Q3 Loss to $51.3M as Bota-Vec Filing Nears
- MeiraGTx Q2 2026: $160.7M Profit, Cash Runway to H2 2028, Oberland Capital Deal Details
- MeiraGTx Q2 2026: $160.7M Net Income, Bota-vec Acquisition, and FDA Breakthrough Designation
- MeiraGTx Swings to $160.7M Q2 Profit, Acquires Bota-vec, and Secures FDA Breakthrough Designation
- MeiraGTx's GV101 Gets FDA Clearance to Enter Phase 2 for Friedreich's Ataxia
Financial Snapshot
Short Interest & Short Volume
10.80 days to coverFINRA reported short interest of 6,641,078 shares in MGTX as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 72.7% of MGTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MGTX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.
New $100M ATM With BofA · Agent Compensation Up to 3.0%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →